key: cord-1016892-ktdqwxjn authors: Tsao, Shih-Ming; Wang, Jann-Yuan; Li, Chien-Feng; Hsieh, Ming-Chang; Wang, Yao-Tung; Chan, Kuei-Chuan; Pan, Hui-Hsien; Lee, Yuan-Ti; Huang, Yi-Wen title: Successful Treatment of a Critical COVID-19 Patient with Tocilizumab date: 2020-10-24 journal: J Formos Med Assoc DOI: 10.1016/j.jfma.2020.10.021 sha: d466cbe558e3753cd42cdb7ce8c321cb56bc3d4d doc_id: 1016892 cord_uid: ktdqwxjn nan 1 Dear editor, Interleukin (IL)-6 has been suggested as one critical mediator in acute respiratory distress syndrome (ARDS) due to severe COVID-19. 1 Given that antiviral agents with a confirmed therapeutic effect for COVID-19 remains lacking, 2 Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report Effective treatment of severe COVID-19 patients with tocilizumab